However, our data supported an effect of SYK inhibition particularly in FLT3 mutated cases, and special TAK-659, which has inhibitory effects against both FLT3 and SYK, seems promising for use in hematological malignancies [18]. The gene discussed is SYK; the disease is hematologic disorder.